Inverse psoriasis: Case presentation and review

American Journal of Clinical Dermatology

Volumn 12, Issue 2, 2011, Pages 143-146

  Syed, Zain U ^a   Khachemoune, Amor ^b  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Botulinum toxin A, therapeutic use; Calcineurin inhibitors, therapeutic use; Calcipotriol, therapeutic use; Calcitriol, therapeutic use; Corticosteroids, therapeutic use; Inverse psoriasis, diagnosis; Inverse psoriasis, pathogenesis; Inverse psoriasis, treatment; Phototherapy; Pimecrolimus, therapeutic use; Tacrolimus, therapeutic use; Vitamin D analogues, therapeutic use.

Indexed keywords

ADALIMUMAB; BOTULINUM TOXIN A; CALCIPOTRIOL; CALCITRIOL; CORTICOSTEROID; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; METHOTREXATE; PIMECROLIMUS; POTASSIUM HYDROXIDE; RETINOID; TACROLIMUS;

ADULT; ARTICLE; AXILLA; BOWEN DISEASE; CANDIDIASIS; CASE REPORT; CLINICAL FEATURE; DARIER DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG WITHDRAWAL; ETHNICITY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INGUINAL REGION; INTERTRIGO; INVERSE PSORIASIS; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; PUVA; SKIN ATROPHY; SKIN BIOPSY; SKIN CULTURE; SKIN DISEASE; SKIN IRRITATION; SKINFOLD; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, CUTANEOUS; AXILLA; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; MIDDLE AGED; PSORIASIS; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 79952171380     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11532060-000000000-00000     Document Type: Article

References (35)

1. Wang G, Li C, Gao T, et al. Clinical analysis of 48 cases of inverse psoriasis: a hospital-based study. Eur J Dermatol 2005; 15 (3): 176-8 (Pubitemid 40733425)
2. Kundacki N, Tursen U, Babikar MOA, et al. The evaluation of the sociodemographic and clinical features of Turkish psoriasis patients. Int J Dermatol 2002; 41: 220-4 (Pubitemid 34601126)
3. van de Kerkhof PCM, Murphy GM, Austad J, et al. Psoriasis of the face and flexures. J Dermatolog Treat 2007; 18: 351-60 (Pubitemid 350223198)
4. Gelfand JM, Stern RS, Nijsten T, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005; 52 (1): 23-6 (Pubitemid 40038931)
5. Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol 2007; 25 (6): 535-46 (Pubitemid 350087600)
6. Fransson J, Storgards K, Hammar H. Palmoplantar lesions in psoriasis patients and their relation to inverse psoriasis, tinea infections and contact allergy. Acta Derm Venereol 1985; 65 (3): 218-23 (Pubitemid 15059092)
7. Habif TP. Psoriasis and other papulosquamous diseases. In:Habif TP. Clinical dermatology. 4th ed. Edinburgh: Mosby, Inc., 2004: 209-66
8. De Rosa G,Mignogna C. The histopathology of psoriasis. Reumatismo 2007; 59 Suppl. 1: 46-8
9. Ghoreschi K, Weigert C, Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin Dermatol 2007; 25 (6): 574-80 (Pubitemid 350087604)
10. Vissers WH, Roelofzen J, De Jong EM, et al. Flexural versus plaque lesions in psoriasis: an immunohistochemical differention. Eur J Dermatol 2005; 15 (1): 13-7 (Pubitemid 40254617)
11. Peramiquel L, Puig L, Dalmau J, et al. Onset of flexural psoriasis during infliximab treatment for Crohn's disease.ClinExp Dermatol 2005Nov; 30: 707-26
12. Pauluzzi P, Boccucci N. Inverse psoriasis induced by terbinafine [letter]. Acta Derm Venereol 1999 Sep; 79 (5): 389 (Pubitemid 29414978)
13. Shelley ED, Shelley WB. Inframammary, intertriginous, and decubital erosions due to etretinate. Cutis 1990 Feb; 45 (2): 111-3 (Pubitemid 20097227)
14. Hassan AS, Simon D, SimonH, et al. Efalizumab-associated papular psoriasis. Arch Dermatol 2007 Jul; 143 (7): 900-6 (Pubitemid 47076489)
15. Rallis E, Koumantak-Mathioudaki E. Pimecrolimus induced tinea incognito masquerading as intertriginous psoriasis. Mycoses 2008 Jan; 51 (1): 71-3 (Pubitemid 350215901)
16. Janniger CK, Schwartz RA, Szepietowski JC, et al. Intertrigo and common secondary skin infections. Am Fam Physician 2005 Sep; 72 (5): 833-8
17. Flystrom I, Bergbrant I, Brared J, et al. Microorganisms in intertriginous psoriasis: no evidence of Candida. Acta Derm Venereol 2003; 83 (2): 121-3 (Pubitemid 36433955)
18. Leibovici V, Alkalay R, Hershko K, et al. Prevalence of Candida on the tongue and intertriginous areas of psoriatic and atopic dermatitis patients. Mycoses 2008 Jan; 51 (1): 63-6 (Pubitemid 350215907)
19. Lisi P. Differential diagnosis of psoriasis. Reumatismo 2007; 59 Suppl. 1: 56-60
20. Cheng S, Edmonds E, Ben-Gashir M, et al. Subcorneal pustular dermatosis: 50 years on. Clin Exp Dermatol 2008 May; 33 (3): 229-33 (Pubitemid 351550656)
21. Breier-Maly J, Ortel B, Breier F, et al. Generalized pustular psoriasis of pregnancy (impetigo herpetiformis). Dermatology 1999; 198 (1): 61-4 (Pubitemid 29086337)
22. Lebwohl MG, Tan M, Meador SL, et al. Limited application of fluticasone propionate ointment, 0.0005% in patients with psoriasis of the face and intertriginous areas. J Am Acad Dermatol 2001 Jan; 44 (1): 77-82 (Pubitemid 32110566)
23. Gribetz C, Ling M, LebwohlM, et al. Pimecrolimus cream 1%in the treatment of intertriginous psoriasis: a double-blind randomized study. J Am Acad Dermatol 2004 Nov; 51 (5): 731-8 (Pubitemid 39516887)
24. Steele JA, Choi C, Kwong PC. Topical tacrolimus in the treatment of inverse psoriasis in children. J Am Acad Dermatol 2005 Oct; 53 (4): 713-6 (Pubitemid 41399952)
25. Brune A,MillerDW, Lin P, et al. Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients. Pediatr Dermatol 2007; 24 (1): 76-80
26. Ortonne JP, Humbert P, Nicolas JF, et al. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 mg/g ointment and calcipotriol 50 mg/g ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003; 148: 326-33 (Pubitemid 36278976)
27. Lebwohl M, Ali S. Treatment of psoriasis: part 2. Systemic therapies. J Am Acad Dermatol 2001; 45 (5): 649-61 (Pubitemid 33032559)
28. Khachemoune A, Guillen S. Psoriasis: disease management with a brief review of new biologics. Dermatol Nurs 2006; 18 (1): 40-9
29. George D, Rosen T. Treatment of inverse psoriasis with efalizumab. J Drugs Dermatol 2009; 8 (1): 74-6
30. Kuehn B. Efalizumab withdrawn. JAMA 2009; 301 (20): 2085
31. Lebwohl M, Ali S. Treatment of psoriasis: part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001; 45 (1): 487-98 (Pubitemid 32917240)
32. Mafong E, Friedman PM, Kauvar ANB, et al. Treatment of inverse psoriasis with the 308nm excimer laser. Dermatol Surg 2002; 28 (6): 530-2 (Pubitemid 34686642)
33. Carrascosa JM, Soria X, Domingo H, et al. Treatment of inverse psoriasis with excimer therapy and tacrolimus ointment. Dermatol Surg 2007; 33: 361-3 (Pubitemid 46328238)
34. Zanchi M, Favot F, Bizzarini M, et al. Botulinum toxin type-A for the treatment of inverse psoriasis. J Eur Acad Dermatol Venereol 2008; 22: 431-6 (Pubitemid 351436912)
35. Kalb RE, Bagel J, Korman NJ, et al. Treatment of intertriginous psoriasis: from the medical board of the National Psoriasis Foundation. J Am Acad Dermatol 2009 Jan; 60 (1): 120-4